ストックスクリーナーアプリを入手
3.57
4.29%
-0.16
アフターアワーズ：
3.58
0.01
+0.28%
Scynexis Inc (SCYX) 最新ニュース
SCYNEXIS Inc (SCYX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
TradingKey - TradingKey
SCYNEXIS Inc (SCYX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
SCYNEXIS Inc (SCYX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
SCYNEXIS, Inc. Revenue Breakdown – NASDAQ:SCYX - TradingView
SCYNEXIS, Inc. Revenue Breakdown – LSE:0L49 - TradingView
SCYNEXIS Inc (SCYX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
SCYNEXIS (SCYX) Slides 2.35% as Biotech Stock Tests Key Support LevelInsider Buying Alerts - dars.gov.et
Federated Hermes (SCYX) group discloses 4.03% Scynexis stake in amended 13G - Stock Titan
FEDERATED HERMES, INC. Acquires 55,207 Shares of SCYNEXIS Inc - GuruFocus
Federated Hermes (SCYX) files 13G/A showing 55,207 shares (4.45%) - Stock Titan
Scynexis Deadline Alert - TMX Newsfile
Enterprise value to EBIT forward of SCYNEXIS, Inc. – NASDAQ:SCYX - TradingView
Enterprise value to EBIT forward of SCYNEXIS, Inc. – FWB:135 - TradingView
Analysts Offer Insights on Healthcare Companies: SCYNEXIS (SCYX) and Abivax SA Sponsored ADR (ABVX) - The Globe and Mail
SCYNEXIS (NASDAQ:SCYX) Is In A Strong Position To Grow Its Business - Sahm
Form DEF 14A Scynexis Inc For: 2 July By Investing.com - Investing.com Nigeria
Scynexis: Buy Rating Reiterated as Rare Disease Pipeline Advances; $32 Price Target Maintained - TipRanks
Form 4 Scynexis Inc For: 30 June By Investing.com - Investing.com Nigeria
SCYNEXIS (SCYX) director receives new RSU and stock option grants - Stock Titan
SCYNEXIS (NASDAQ: SCYX) director gets RSU and option awards - Stock Titan
SCYNEXIS (SCYX) director Armando Anido granted stock units and options - Stock Titan
SCYNEXIS (SCYX) director receives new stock and option awards - Stock Titan
SCYNEXIS (SCYX) director Ann Hanham receives stock and option grants - Stock Titan
Enterprise value to revenue forward of SCYNEXIS, Inc. – FWB:135 - TradingView
Scynexis (SCYX) Launches Phase 1 Study for SCY-770 in Kidney Dis - GuruFocus
SCYNEXIS Initiates Phase 1 Study of SCY-770, a Novel AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) - The Manila Times
SCYNEXIS Inc. (SCYX) Q1 2026 Earnings: Wider-than-Expected Loss on No Reported Revenue; Stock Rises 5.17%EBITDA Analysis - dars.gov.et
Enterprise value to revenue forward of SCYNEXIS, Inc. – NASDAQ:SCYX - TradingView
Enterprise value to revenue forward of SCYNEXIS, Inc. – GETTEX:135 - TradingView
Price to book forward of SCYNEXIS, Inc. – NASDAQ:SCYX - TradingView
Price to earnings forward of SCYNEXIS, Inc. – GETTEX:135 - TradingView
Price to sales forward of SCYNEXIS, Inc. – NASDAQ:SCYX - TradingView
Price to book forward of SCYNEXIS, Inc. – GETTEX:135 - TradingView
Enterprise value to EBITDA forward of SCYNEXIS, Inc. – NASDAQ:SCYX - TradingView
Price to sales forward of SCYNEXIS, Inc. – GETTEX:135 - TradingView
Enterprise value to EBITDA forward of SCYNEXIS, Inc. – GETTEX:135 - TradingView
SCYNEXIS (SCYX) Edges Higher as Support Holds, Resistance AwaitsRetracement Entry - dars.gov.et
SCYNEXIS Shareholders Approve Governance and Equity Plan Changes - TipRanks
SCYNEXIS (SCYX) expands authorized stock and registers 87M shares for resale - Stock Titan
SCYNEXIS Inc (SCYX) Valuation: PE, PB & Fair Value Analysis - TradingKey
SCYNEXIS, Inc. Actuals & Estimates (NASDAQ:SCYX) - TradingView
SCYX Forecast — Price Target — Prediction for 2027 - TradingView
SCYNEXis (SCYX) Surges 6.6% – Testing Key Resistance at $4.25Low Beta Factor - dars.gov.et
SCYNEXIS Inc (SCYX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
SCYNEXIS Inc (SCYX) Institutional Confidence - TradingKey
SCYNEXIS Inc (SCYX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
SCYNEXIS Inc (SCYX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
SCYNEXIS (SCYX) Holds Near Support Amid Quiet TradingFast Moving Stocks - newsline.com
SCYNEXIS Q1 2026 Earnings: EPS Misses Estimates as Company Reports No RevenueEPS Revision Trend - dars.gov.et
SCYNEXIS, Inc. Hits New 52-Week High of $5.62, Up 157.49% - MarketsMojo
SCYNEXIS (SCYX) Picks Up Slightly as Stock Bounces Within Established RangeDiagonal Spread Trade - newsline.com
SCYNEXIS (SCYX) Slides 2.6% as Stock Approaches Key SupportATR Trailing Stop - newsline.com
SCYX Q1 2026 Earnings: Major EPS Miss Sparks Negative Market ReactionEarnings Season Preview - DonanımHaber
Total liabilities of SCYNEXIS, Inc. – MUN:135 - TradingView
SCYNEXIS, Inc. Balance Sheet – MUN:135 - TradingView
Net debt of SCYNEXIS, Inc. – FWB:135 - TradingView
Pretax income of SCYNEXIS, Inc. – TRADEGATE:135 - TradingView
Free cash flow of SCYNEXIS, Inc. – FWB:135 - TradingView
SCYNEXIS, Inc. Cash Flow – MUN:135 - TradingView
0.30%
2.01%
大文字化:
|
ボリューム (24 時間):